Leishmaniasis and various immunotherapeutic approaches.
Taslimi Y, Zahedifard F, Rafati S.
Parasitology. 2018 Apr;145(4):497-507. doi: 10.1017/S003118201600216X. Epub 2016 Dec 15.
Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs.
Kaye PM, Cruz I, Picado A, Van Bocxlaer K, Croft SL.
Semin Immunopathol. 2020 Jun;42(3):247-264. doi: 10.1007/s00281-020-00788-y. Epub 2020 Mar 9.
Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani M, Farhoudi R.
Drug Des Devel Ther. 2017 Dec 22;12:25-40. doi: 10.2147/DDDT.S146521. eCollection 2018.
Editorial: Biomarkers in Leishmaniasis.
Carrillo E, Moreno J.
Front Cell Infect Microbiol. 2019 Nov 12;9:388. doi: 10.3389/fcimb.2019.00388. eCollection 2019.
Visceral leishmaniasis: An overview of vaccine adjuvants and their applications.
Ratnapriya S, Keerti, Sahasrabuddhe AA, Dube A.
Vaccine. 2019 Jun 12;37(27):3505-3519. doi: 10.1016/j.vaccine.2019.04.092. Epub 2019 May 15.
NKT cells in leishmaniasis.
Zamora-Chimal J, Hernández-Ruiz J, Becker I.
Immunobiology. 2017 Apr;222(4):641-646. doi: 10.1016/j.imbio.2016.11.014. Epub 2016 Dec 5.
Peptide Vaccines for Leishmaniasis.
De Brito RCF, Cardoso JMO, Reis LES, Vieira JF, Mathias FAS, Roatt BM, Aguiar-Soares RDDO, Ruiz JC, Resende DM, Reis AB.
Front Immunol. 2018 May 11;9:1043. doi: 10.3389/fimmu.2018.01043. eCollection 2018.
Host Mast Cells in Leishmaniasis: Friend or Foe?
Naqvi N, Srivastava R, Selvapandiyan A, Puri N.
Trends Parasitol. 2020 Dec;36(12):952-956. doi: 10.1016/j.pt.2020.09.010. Epub 2020 Oct 12.
Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review.
Kelleci K, Allahverdiyev A, Bağirova M, Ihlamur M, Abamor EŞ.
J Vector Borne Dis. 2023 Apr-Jun;60(2):125-141. doi: 10.4103/0972-9062.361179.
Immunotherapy for visceral leishmaniasis: A trapeze of balancing counteractive forces.
Mazire PH, Saha B, Roy A.
Int Immunopharmacol. 2022 Sep;110:108969. doi: 10.1016/j.intimp.2022.108969. Epub 2022 Jun 20.
